focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yes you're absolutely right in that quote it most definitely refers to Moditope but in other places - SCOPE results presentation for example she uses the term for SCIB1. Perhaps she meant the ImmunoBody platform as a whole rather than SCIB1.
"SCIB1 a DC targeting DNA vaccine gives at impressive 85% response rate in combination with ipilimumab and nivolumab in advanced melanoma. Citrullination occurs in stressed tumor cells and makes an excellent target for a universal cancer vaccine. Modi-1 targeting citrullination is currently in phase II clinical trial."
I believe the first sentence is about SCIB1 and the second and third sentences are about Modi1 and citrullination.
So the universal vaccine refers to targeting citrullination in general. Citrullination is not a target for SCIB1 but it is a target for Modi1.
I doubt whether Lindy considers Modi1, as it stands, to be a universal vaccine. I think she is just looking ahead to designing a Moditope vaccine targeting the very best combination of citrullinated epitopes and thereby being effective against a wide range of cancers.
Ray - so what did she mean when describing SCIB1 as a potential universal vaccine?
Lindy has always said that citrullination occurs on many different proteins and within each protein specific epitopes.
Modi-1 comprises just three citrullinated peptides, two derived from vimentin and one from α-enolase.
From memory, Lindy's team initially identified of the order of 30 different citrullinated epitopes that could be targeted. At the time 8 had been tested and all 8 showed a promising response.
I think the point that Lindy is making is that Modi1 could possibly just be scratching the surface of what could be eventually achieved by targeting citrullination.
So, I think miavoce is correct in stating
"Universal could equally well mean that it can be applied to all / multiple cancers as citrullination is a common feature across them."
Ee
Possibly but they also used that term for SCIB1 which of course is a melanoma only vaccine and nothing to do with citrullination so I still think Chelsea's off the shelf as opposed to personalised is the intended meaning. Quite right too to highlight the advantage of Scancell's vaccines over those generating so much interest and excitment from BioNTech/Moderna .
The “Universal cancer vaccine” comment refers to a process (citrullination) which is common across a number of tumour types. Hence if you target the process, you can address different types of cancer and target T-cells at them.
The distinction between personalised vaccines and “ready made” alternatives is, IMO, somewhat different. But, either way, the vaccine has potentially got a broad range of applications.
Chelsea, I agree - am pretty it's universal as distinct from personalised cancer vaccines.
It could also mean that all stressed cancer cells go through citrullination and can therefore be targeted. The trick being that you have to create an environment where that stress occurs.
That is not an easy task but with enough research into the mechanisms plus the added aggression of the immune system created by Checkpoint Inhibitors, would it not be possible in all cases ??
Universal could equally well mean that it can be applied to all / multiple cancers as citrullination is a common feature across them.
I would assume universal, is just a substitute for off the shelf.
Just looking at the link to Lindy’s talk at the Immuno-Oncology Summit, Lindy makes reference to a "universal cancer vaccine". Maybe I am mistaken but I have not heard her refer to a "universal cancer vaccine" previously :-
https://www.immuno-oncologyeurope.com/cancer-vaccines#RobertMeehan
"SCIB1 a DC targeting DNA vaccine gives at impressive 85% response rate in combination with ipilimumab and nivolumab in advanced melanoma. Citrullination occurs in stressed tumor cells and makes an excellent target for a universal cancer vaccine. Modi-1 targeting citrullination is currently in phase II clinical trial."
Results as a mono therapy will show about a 60% rate similar to Scib1 as a mono. It is Sclp belief that in combination with the CPI rates will again be similar to the SCIB1 combo.
Up at the 85 to 90%